Insider · CIK 0001767300
James Kelly Ganjei
Files at INMB (Inmune Bio, Inc.). First filing -, latest -.
In brief
James Kelly Ganjei files SEC Form 4 as director at INMB (Inmune Bio, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; James Kelly Ganjei has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 18 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 1, 2025 | INMB Inmune Bio, Inc. | AGrant or award Option (right to buy)derivative | +150,000 | $0.00 | $0 | 150,000 | Dec 2, 2025 |
| Nov 18, 2025 | INMB Inmune Bio, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -108,000 | - | - | 0 | Nov 18, 2025 |
| Nov 18, 2025 | INMB Inmune Bio, Inc. | AGrant or award Stock Option (right to buy)derivative | +108,000 | - | - | 108,000 | Nov 18, 2025 |
| Nov 18, 2025 | INMB Inmune Bio, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -108,000 | - | - | 0 | Nov 18, 2025 |
| Nov 18, 2025 | INMB Inmune Bio, Inc. | AGrant or award Stock Option (right to buy)derivative | +108,000 | - | - | 108,000 | Nov 18, 2025 |
| Nov 18, 2025 | INMB Inmune Bio, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -15,975 | - | - | 0 | Nov 18, 2025 |
| Nov 18, 2025 | INMB Inmune Bio, Inc. | AGrant or award Stock Option (right to buy)derivative | +15,975 | - | - | 15,975 | Nov 18, 2025 |
| Nov 18, 2025 | INMB Inmune Bio, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -19,025 | - | - | 0 | Nov 18, 2025 |
| Nov 18, 2025 | INMB Inmune Bio, Inc. | AGrant or award Stock Option (right to buy)derivative | +19,025 | - | - | 19,025 | Nov 18, 2025 |
| Nov 18, 2025 | INMB Inmune Bio, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -35,000 | - | - | 0 | Nov 18, 2025 |
| Nov 18, 2025 | INMB Inmune Bio, Inc. | AGrant or award Stock Option (right to buy)derivative | +35,000 | - | - | 35,000 | Nov 18, 2025 |
| Nov 18, 2025 | INMB Inmune Bio, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -35,000 | - | - | 0 | Nov 18, 2025 |
| Nov 18, 2025 | INMB Inmune Bio, Inc. | AGrant or award Stock Option (right to buy)derivative | +35,000 | - | - | 35,000 | Nov 18, 2025 |
| Nov 18, 2025 | INMB Inmune Bio, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -32,500 | - | - | 0 | Nov 18, 2025 |
| Nov 18, 2025 | INMB Inmune Bio, Inc. | AGrant or award Stock Option (right to buy)derivative | +32,500 | - | - | 32,500 | Nov 18, 2025 |
| Nov 18, 2025 | INMB Inmune Bio, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -12,500 | - | - | 0 | Nov 18, 2025 |
| Nov 18, 2025 | INMB Inmune Bio, Inc. | AGrant or award Stock Option (right to buy)derivative | +12,500 | - | - | 12,500 | Nov 18, 2025 |
| Dec 5, 2024 | INMB Inmune Bio, Inc. | AGrant or award Option (right to buy)derivative | +32,500 | $0.00 | $0 | 32,500 | Dec 9, 2024 |
Questions about James Kelly Ganjei
Answered from the filings on this page, as of the latest one.
Is James Kelly Ganjei buying or selling?
James Kelly Ganjei has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did James Kelly Ganjei's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and James Kelly Ganjei has 0.
Where does James Kelly Ganjei file Form 4?
James Kelly Ganjei has filed Form 4 at INMB (Inmune Bio, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.